24/7 Market News Snapshot 16 October, 2024 – GRI Bio, Inc. Common Stock (NASDAQ:GRI)

October 16, 2024

DENVER, Colo., 16 October, 2024 (247marketnews.com) – (NASDAQ:GRI) are discussed in this article.
GRI Bio, Inc. (GRI) has experienced a significant increase in its stock price, currently trading at $0.417, reflecting a 12.70% rise from the previous close of $0.370. The stock opened at $0.41, exhibiting strong momentum with a trading volume of 5.03 million shares. This upward movement suggests heightened investor interest, with the stock recently breaking above the former resistance level of $0.40, indicating potential for further gains. Investors are encouraged to observe upcoming trading volumes and technical indicators that may affirm this trend, keeping in mind the inherent volatility often associated with low-price stocks.

Concurrently, GRI Bio is advancing its innovative treatment for Idiopathic Pulmonary Fibrosis (IPF) through its lead program, GRI-0621. Recent preclinical findings presented at the 22nd International Colloquium on Lung and Airway Fibrosis revealed a significant reduction in inflammatory and fibrotic markers associated with the disease. The research focuses on the role of invariant Natural Killer T (iNKT) cells in worsening lung fibrosis, establishing that GRI-0621 dramatically improved various pathological conditions in preclinical models, including reduced lung injury and collagen deposition. This suggests that targeting iNKT cell activity may provide a promising therapeutic option for managing IPF, a progressive lung disease with limited treatment options.

CEO Marc Hertz expressed optimism about the preclinical data, highlighting GRI-0621’s potential to positively impact the lives of IPF patients. The company expects interim results from its Phase 2a biomarker study in the fourth quarter of 2024, followed by topline results in early 2025. With current treatment options for IPF being limited and often accompanied by significant side effects, GRI Bio’s dual agonist, GRI-0621, aims to interrupt the harmful inflammatory processes while restoring immune balance. The company remains committed to developing groundbreaking therapies for inflammatory and fibrotic diseases, aspiring to enhance patient outcomes and overall quality of life.

Related news for (GRI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.